824 related articles for article (PubMed ID: 31581940)
1. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR
J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940
[TBL] [Abstract][Full Text] [Related]
2. Meta-microRNA Biomarker Signatures to Classify Breast Cancer Subtypes.
Oztemur Islakoglu Y; Noyan S; Aydos A; Gur Dedeoglu B
OMICS; 2018 Nov; 22(11):709-716. PubMed ID: 30388053
[TBL] [Abstract][Full Text] [Related]
3. microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers is Mainly Dependent on HER2 Status-A Pilot Study.
Kunc M; Popęda M; Niemira M; Szałkowska A; Bieńkowski M; Pęksa R; Łacko A; Radecka BS; Braun M; Pikiel J; Litwiniuk M; Pogoda K; Iżycka-Świeszewska E; Krętowski A; Żaczek AJ; Biernat W; Senkus-Konefka E
Diagnostics (Basel); 2020 Aug; 10(9):. PubMed ID: 32825530
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer.
McDermott AM; Miller N; Wall D; Martyn LM; Ball G; Sweeney KJ; Kerin MJ
PLoS One; 2014; 9(1):e87032. PubMed ID: 24498016
[TBL] [Abstract][Full Text] [Related]
5. Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients.
Sakurai M; Masuda M; Miki Y; Hirakawa H; Suzuki T; Sasano H
Int J Biol Markers; 2015 May; 30(2):e190-9. PubMed ID: 25907662
[TBL] [Abstract][Full Text] [Related]
6. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.
Leivonen SK; Sahlberg KK; Mäkelä R; Due EU; Kallioniemi O; Børresen-Dale AL; Perälä M
Mol Oncol; 2014 Feb; 8(1):93-104. PubMed ID: 24148764
[TBL] [Abstract][Full Text] [Related]
7. Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen.
McFall T; McKnight B; Rosati R; Kim S; Huang Y; Viola-Villegas N; Ratnam M
J Biol Chem; 2018 Jan; 293(4):1163-1177. PubMed ID: 29162724
[TBL] [Abstract][Full Text] [Related]
8. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
Wang B; Li J; Sun M; Sun L; Zhang X
IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
[TBL] [Abstract][Full Text] [Related]
10. Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes.
Li JY; Jia S; Zhang WH; Zhang Y; Kang Y; Li PS
Asian Pac J Cancer Prev; 2013; 14(5):3197-203. PubMed ID: 23803104
[TBL] [Abstract][Full Text] [Related]
11. Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection.
Matamala N; Vargas MT; González-Cámpora R; Miñambres R; Arias JI; Menéndez P; Andrés-León E; Gómez-López G; Yanowsky K; Calvete-Candenas J; Inglada-Pérez L; Martínez-Delgado B; Benítez J
Clin Chem; 2015 Aug; 61(8):1098-106. PubMed ID: 26056355
[TBL] [Abstract][Full Text] [Related]
12. miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.
Endo Y; Toyama T; Takahashi S; Yoshimoto N; Iwasa M; Asano T; Fujii Y; Yamashita H
Endocr Relat Cancer; 2013 Feb; 20(1):91-102. PubMed ID: 23183268
[TBL] [Abstract][Full Text] [Related]
13. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study.
Kodahl AR; Lyng MB; Binder H; Cold S; Gravgaard K; Knoop AS; Ditzel HJ
Mol Oncol; 2014 Jul; 8(5):874-83. PubMed ID: 24694649
[TBL] [Abstract][Full Text] [Related]
14. Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p.
Calvano Filho CM; Calvano-Mendes DC; Carvalho KC; Maciel GA; Ricci MD; Torres AP; Filassi JR; Baracat EC
Tumour Biol; 2014 Aug; 35(8):7733-41. PubMed ID: 24810926
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA regulation of progesterone receptor in breast cancer.
Gilam A; Shai A; Ashkenazi I; Sarid LA; Drobot A; Bickel A; Shomron N
Oncotarget; 2017 Apr; 8(16):25963-25976. PubMed ID: 28404930
[TBL] [Abstract][Full Text] [Related]
16. MTUS1 and its targeting miRNAs in colorectal carcinoma: significant associations.
Ozcan O; Kara M; Yumrutas O; Bozgeyik E; Bozgeyik I; Celik OI
Tumour Biol; 2016 May; 37(5):6637-45. PubMed ID: 26643896
[TBL] [Abstract][Full Text] [Related]
17. miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites.
Rinnerthaler G; Hackl H; Gampenrieder SP; Hamacher F; Hufnagl C; Hauser-Kronberger C; Zehentmayr F; Fastner G; Sedlmayer F; Mlineritsch B; Greil R
Int J Mol Sci; 2016 Jan; 17(2):. PubMed ID: 26821018
[TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
[TBL] [Abstract][Full Text] [Related]
19. Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer.
Johannessen C; Moi L; Kiselev Y; Pedersen MI; Dalen SM; Braaten T; Busund LT
PLoS One; 2017; 12(10):e0186658. PubMed ID: 29073169
[TBL] [Abstract][Full Text] [Related]
20. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.
Chang YY; Kuo WH; Hung JH; Lee CY; Lee YH; Chang YC; Lin WC; Shen CY; Huang CS; Hsieh FJ; Lai LC; Tsai MH; Chang KJ; Chuang EY
Mol Cancer; 2015 Feb; 14():36. PubMed ID: 25888956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
